Long-term cost effectiveness of ticagrelor in patients with acute coronary syndromes in Thailand

Health Economics Review

Table 4 Total costs used in the model ^a

Items	Cost (THB)	Sources
One-year decision tree
*Ticagrelor*
Annual drug cost	34,368	Manufacturer’s price
No event	117,404	Nikolic [8], Riewpaiboon [16]
Non-fatal MI	204,851	Nikolic [8], Riewpaiboon [16], Central office for Healthcare Information [17]
Non-fatal stroke	141,918	Nikolic [8], Riewpaiboon [16]
Death any cause	120,132	Nikolic [8], Riewpaiboon [16]
*Clopidogrel*
Annual drug cost (branded price)	26,473	DMSIC [17]
Annual drug cost (generic price)	344	DMSIC [17]
No event	120,307	Nikolic [8], Riewpaiboon [16]
Non-fatal MI	207,753	Nikolic [8], Riewpaiboon [16], Central office for Healthcare Information [17]
Non-fatal stroke	144,821	Nikolic [8], Riewpaiboon [16]
Death any cause	123,034	Nikolic [8], Riewpaiboon [16]
Markov model
Total cost MI 1^st year Markov model	168,196	Anukoolsawat [4]
Total cost MI 2^nd year and onward	35,926	Anukoolsawat [4]
Total cost stroke 1^st year Markov model	79,800	Tamteeranon [15]
Total cost stroke 2^nd year and onward	12,642	Tamteeranon [15]
Total cost of no event	21,866	Anukoolsawat [4]

^aDetailed table of Thai hospital charges and unit cost (Baht) for the resource use collected in the PLATO trial provided in the Additional file 1: Table S1.

ISSN: 2191-1991